Mon. May 25th, 2026
Spread the love

ALIMA (The Alliance for International Medical Action) is an international medical NGO dedicated to saving lives and providing care to the most vulnerable populations. Our work is guided by humanitarian principles, medical ethics, and a strong commitment to innovation, research, and partnership.

ALIMA operates in several countries across Africa and beyond, delivering healthcare in areas such as maternal and child health, nutrition, mental health, and epidemic response.

Job Title: Clinical Research Assistant

 

Location: Abuja  (with frequent travel to Owo, Irrua, Bauchi, and other sites)
Employment Type: Full-time
Reports to: Research Coordinator – Nigeria / INTEGRATE Coordination Team
Contract Duration: 6 months
Level: 09

Context

  • ALIMA is implementing the INTEGRATE clinical trial in Nigeria, a multinational research initiative focused on improving treatment outcomes for Lassa Fever. The project combines clinical care with operational research to strengthen evidence-based medical responses and local research capacity.

Mission & Objectives

  • The Clinical Research Assistant (CRA) supports the monitoring and quality assurance of the INTEGRATE clinical trial in Nigeria. He/she ensures that study activities comply with Good Clinical Practice (GCP), the research protocol, and ethical and regulatory standards.
  • The CRA will regularly visit study sites to monitor progress, verify data accuracy, and assist with problem-solving related to trial operations.

Main Responsibilities
Clinical Monitoring and Quality Assurance:

  • Monitor compliance with Good Clinical Practice (ICH E6 R2) and study SOPs at each site.
  • Verify the accuracy and consistency of data entries with source documents.
  • Ensure timely reporting of adverse and serious adverse events (SAEs).
  • Support site staff in resolving data queries and protocol deviations.
  • Prepare and submit detailed monitoring visit reports to the INTEGRATE coordination team.
  • Verify that trial documentation (regulatory binders, consent forms, logs) are current and compliant.
  • Participate in end-of-study closure activities.

Coordination and Communication:

  • Act as the liaison between site teams, ALIMA coordination, and international monitors.
  • Participate in weekly coordination meetings and contribute to quality improvement.
  • Communicate any field-level challenges, deviations, or technical needs promptly.
  • Support training and capacity-building activities for local site staff on GCP and study procedures.

Compliance, Ethics, and Data Integrity:

  • Ensure strict confidentiality of patient and trial data.
  • Monitor adherence to national ethics committee and regulatory authority requirements.
  • Uphold ALIMA’s principles of data protection, transparency, and accountability.
  • Ensure all trial activities adhere to ALIMA’s policies on PSEA, safety, and ethical conduct.

 

Infection Prevention and Control (IPC):

  • Comply at all times with Lassa fever IPC protocols when in wards and laboratories.
  • Enforce adherence to biosafety and PPE procedures during field visits.
  • Report any IPC breaches or exposure incidents to the Safety Focal Point.

Contribution to Research Development:

  • Assist in documentation and analysis of trial progress.
  • Contribute to local capacity building by mentoring junior research staff.
  • Support the dissemination of research outcomes at local and national levels, under supervision.

Professional Conduct:

  • Maintain professional behavior in accordance with ALIMA’s values and ethics.
  • Show initiative and autonomy in problem-solving while maintaining team spirit.
  • Participate actively in team meetings, briefings, and training sessions.
  • Promote an environment of respect, collaboration, and continuous learning.

Experience And Skills
Education:

  • Medical, Paramedical, or Life Sciences Diploma (Medicine, Nursing, Pharmacy, Laboratory Sciences).
  • Additional certification in Clinical Research or GCP required.
  • A postgraduate degree in Public Health, Epidemiology, or Clinical Research is an asset.

Experience:

  • 1 – 2 years of experience in clinical research or trial monitoring.
  • Previous work with infectious diseases or hospital-based studies preferred.
  • Experience with international NGOs or multi-partner projects is desirable.

Skills:

  • Strong knowledge of GCP, clinical monitoring techniques, and regulatory compliance.
  • Excellent command of medical and research terminology.
  • Strong computer proficiency (MS Office Suite, EDC systems).
  • Ability to draft clear and precise reports.
  • Excellent interpersonal, communication, and organizational skills.
  • Ability to work under pressure and manage priorities effectively.

Languages:

  • Fluent in English (spoken and written).
  • Knowledge of Hausa, Yoruba, Pidgin, or other local languages in Ondo and Bauchi States is an advantage.

Personal Qualities:

  • Rigor, reliability, and integrity.
  • Adaptability and flexibility in complex field settings.
  • Respect for confidentiality and ethical sensitivity.
  • Mobility and willingness to travel regularly to inclusion sites.
  • Commitment to humanitarian and scientific values.

Conditions

  • Contract type: Local Nigerian employment contract (6 months).
  • Salary level: According to ALIMA’s national salary scale (Level 09).
  • Duty station: Abuja, with frequent travel to trial sites (Owo, Irrua, Bauchi).
  • Benefits: Health coverage, field per diem, Annual Leave, professional training in GCP and clinical monitoring.

 

 

Application Closing Date
13th April, 2026.

 

METHOD OF APPLICATION 
Interested and qualified candidates should use link below to Apply.

CLICK HERE TO APPLY

The post Clinical Research Assistant at Alliance for International Medical Action (ALIMA) appeared first on Advert By Dotifi .Com Domains for almajiri.com.ng | Best African Hausa Music Blog, Entertainment ,News and Gossips .

By 9jabook

You missed

From Tramadol to Canadian to Exol-5 The New Drug Destroying Nigerian Youths An Investigative Article .From Tramadol to Canadian to Exol-5: The New Drug Destroying Nigerian Youths An Investigative Report on the Shifting Landscape of Substance Abuse in Nigeria Nigeria faces a severe and evolving drug crisis, particularly among its youth. What began with the widespread abuse of Tramadol has progressed through mixtures like “Canadian” to newer pharmaceutical diversions such as Exol-5. This shift reflects deeper issues: easy access to prescription drugs, weak regulation, socioeconomic pressures, and aggressive street-level marketing. NDLEA operations and health studies reveal a public health emergency that threatens an entire generation. Phase 1: The Tramadol Epidemic (2010s–Early 2020s) Tramadol, a synthetic opioid prescribed for moderate to severe pain, became Nigeria’s most notorious street drug. Cheap, potent, and widely smuggled (often from India and other Asian countries), it offered users energy, euphoria, and pain relief — appealing to commercial drivers, laborers, students, and young men seeking confidence or stamina. Scale of the Problem: Millions of tablets seized annually by NDLEA. High prevalence among young males aged 15–35. Linked to increased crime, sexual violence, organ damage (kidney failure, seizures), and mental health breakdowns. Contributed to broader opioid misuse alongside codeine cough syrups. Government responses included tighter import controls and public awareness campaigns, but these only displaced demand to other substances rather than eliminating it. Phase 2: The Rise of “Canadian” (Mid-2020s) “Canadian” or “Canadian Loud” emerged as a popular code for high-grade cannabis (often indica-dominant strains) or cannabis mixed with other synthetics. It gained traction as users sought alternatives or combinations to Tramadol’s effects. This phase marked a move toward imported or locally cultivated premium weed, sometimes laced with stronger chemicals. Youths in urban centers like Lagos, Kano, Jos, and Onitsha embraced it for its perceived “cleaner” high compared to opioids. However, it fueled polydrug use — combining cannabis with opioids, sedatives, or alcohol — amplifying health risks. Phase 3: Exol-5 – The Current Threat (2024–2026) Exol-5 (Benzhexol Hydrochloride / Trihexyphenidyl 5mg), originally a prescription medication for Parkinson’s disease and drug-induced movement disorders, has become the latest pharmaceutical being heavily abused. Why Exol-5? Euphoric Effects: Users report intense euphoria, hallucinations, and a sense of detachment — making it attractive as a cheap “upper” or escape. Accessibility: Sold over-the-counter or on the black market despite being a controlled prescription drug. NDLEA has seized millions of pills in single operations (e.g., 3.1 million pills in Kano in late 2024, and over 5.6 million combined with Tramadol in other busts). Street Names: Exol, Artane, Benzhexol, “Farin Mallam” (in Northern Nigeria). Demographics: Prevalent among youths, laborers, and even psychiatric patients who divert prescriptions. Studies show abuse rates as high as 25% among certain outpatient groups. Health Consequences: Anticholinergic toxicity: Confusion, dry mouth, blurred vision, urinary retention, constipation, and in high doses — delirium, psychosis, seizures, and heart issues. Long-term: Cognitive impairment, addiction, exacerbated mental health disorders. Often mixed with Tramadol, codeine, or cannabis, creating dangerous synergies. In cities like Jos, Exol-5 sits alongside diazepam, Rohypnol, and Tramadol on street markets, easily available to teenagers and young adults. Why This Evolution Continues Supply-Side Failures: Porous borders, corrupt officials, and overproduction of pharmaceuticals enable diversion. Demand Drivers: Unemployment, poverty, peer pressure, trauma, and the pursuit of performance enhancement (e.g., for “hustle” culture). Weak Regulation: Many pharmacies sell restricted drugs without prescriptions. Online and street vendors fill gaps. Displacement Effect: Cracking down on one substance (Tramadol/codeine) pushes users and dealers toward the next available option. NDLEA reports ongoing large seizures, but the problem persists due to high profitability and low risk for mid-level distributors. Broader Impacts on Nigerian Youths Education: Increased dropout rates and poor academic performance. Mental Health: Rising cases of psychosis and depression. Economy: Lost productivity among the working-age population. Crime and Violence: Drug-fueled robberies, cultism, and family breakdowns. Public Health System Strain: Overburdened hospitals treating overdoses and chronic complications. Young people aged 15–39 remain the hardest hit, with national surveys showing drug use prevalence significantly above global averages. What Must Be Done Stronger Enforcement: Consistent prosecution of corrupt enablers and large-scale traffickers. Regulation: Crackdown on rogue pharmacies and better tracking of prescription drugs. Prevention & Rehabilitation: School programs, community outreach, and expanded treatment centers (currently woefully inadequate). Economic Alternatives: Address root causes like youth unemployment. Public Awareness: Honest campaigns highlighting real dangers of “Exol-5” and similar drugs. Conclusion From Tramadol’s opioid grip to “Canadian” cannabis culture and now Exol-5’s anticholinergic highs, Nigeria’s drug crisis is mutating faster than responses can contain it. Exol-5 represents the dangerous new frontier — a legitimate medicine turned youth destroyer due to misuse and greed. Without urgent, multi-layered intervention — combining supply disruption, demand reduction, and socioeconomic support — an entire generation risks being lost to addiction. The time for half-measures is over. Nigeria’s future depends on winning this fight.